Assessing the Clinical Benefit of Systemic Adjuvant Therapies for Early Breast Cancer

Bestimmung des klinischen Nutzens systemischer adjuvanter Therapien beim frühen Mammakarzinom

Authors
Volker Möbus¹, Susanne Hell², Marcus Schmidt³

Affiliations
1 Klinik für Gynäkologie und Geburtshilfe, Klinikum Frankfurt-Höchst, Frankfurt, Germany
2 Roche Pharma AG, Grenzach-Wyhlen, Germany
3 Klinik und Poliklinik für Geburtshilfe und Frauen-gesundheit, Universitätsmedizin Mainz, Mainz, Germany

Key words
early breast cancer, adjuvant therapy, clinical benefit

Schlüsselwörter
frühes Mammakarzinom, adjuvante Therapie, klinischer Nutzen

received 8.6.2017
revised 8.9.2017
accepted 11.9.2017

Bibliography
DOI https://doi.org/10.1055/s-0043-119542
Geburtsh Frauenheilk 2017; 77: 1079–1087 © Georg Thieme Verlag KG Stuttgart · New York | ISSN 0016-5751

Correspondence
Prof. Dr. med. Volker Möbus
Klinik für Gynäkologie und Geburtshilfe, Klinikum Frankfurt-Höchst
Gotenstraße 6–8, 65929 Frankfurt a. M., Germany
volker.moebus@KlinikumFrankfurt.de

ZUSAMMENFASSUNG
Introduction

In the wake of the recent rapid advances in molecular biology, oncology therapy is currently undergoing major changes, moving towards treatment geared to the individual tumor biology. The new targeted therapies need to be benchmarked against existing therapy options which are already available. Bearing this in mind and in view of the cost of these innovations, the discussion about the terms clinical benefit and clinical relevance has become highly topical. This is demonstrated by the fact that scientific societies such as the American Society of Clinical Oncology (ASCO) and the European Society of Medical Oncology (ESMO) are working to develop criteria which can be used to assess the clinical benefits of new medications [1, 2].

The question of clinical relevance is currently also an issue when assessing recent developments in adjuvant systemic therapy for early breast cancer. Two phase III studies have reported positive results for new targeted drugs used in systemic adjuvant therapy to treat early HER2-positive breast cancer, i.e. there was a significant improvement in the primary study endpoint “disease-free survival” [3, 4]. Adjuvant studies with CDK4/6 inhibitors and immune checkpoint inhibitors have been launched or are in the final discussion stages of compiling their study protocols [5–11]. But how can the clinical benefit of an adjuvant therapy to treat early breast cancer be measured? Which improvements resulting from the new therapy should be classified as clinically relevant?

This review article discusses the issue of clinical relevance with regard to adjuvant therapies for early breast cancer. The discussion looks at examples from the evidence for various established adjuvant therapy standards. This study deliberately chose not to focus on individual studies but instead to look at large meta-analyses and the findings on recurrence rates and overall mortality rates, similar to the approach used by ASCO, ESMO and the European and American regulatory authorities EMA and FDA [12, 13].

Systemic Therapy of Early Breast Cancer – Rationale and Medical Need

Today, breast cancer is viewed as a generalized systemic disease. Systemic therapy is consequently an integral part of the treatment of patients with early breast cancer [14–19]. The goal of this approach is to eliminate micro-metastases which are already present in the early stages of disease and thereby to prevent recurrence and increase the probability of cure [20, 21]. The results of neoadjuvant chemotherapy administered before primary surgery and adjuvant chemotherapy administered after surgery are comparable in terms of overall survival. Because of this, the AGO recommends considering neoadjuvant administration for patients with an indication for chemotherapy [18].

The relative 10-year survival of women with breast cancer is now 82%. Overall, the mortality rates for breast cancer have dropped continually since the 1990s; nevertheless it remains a health issue in Germany [22]. In 2013, 71,640 women in Germany developed breast cancer and 17,853 women died of it. The Robert Koch Institute anticipates that there will be 77,600 new cases of breast cancer in Germany in 2020 [22].

Despite the many successes, the above-mentioned figures show that there is still a real medical need to improve systemic therapies for patients with early breast cancer.

A good example for this is HER2-positive early breast cancer. Adjuvant therapy with trastuzumab for 1 year resulted in a clear and significant improvement in disease-free survival (DFS) (hazard ratio [HR] = 0.60; 95% confidence interval [CI]: 0.50–0.71, p < 0.00001) and in overall survival (OS) (HR = 0.66; 95% CI: 0.57–0.77, p < 0.00001) for patients with HER2-positive early breast cancer [23]. However, after 10 years 25–31% of women who had received adjuvant therapy with trastuzumab in the studies used to obtain approval of the drug went on to develop recurrence, in two thirds of cases in the form of distant metastasis. Up to 19% of patients participating in the study had died during the follow-up period of 10 years [24–26]. In the pivotal studies NCCTG 9831/NSABP B-31, BCIRG 006 and HERA, depending on the mean follow-up time, the percentage of deaths from breast cancer ranged from 72% after 8.3 years, to 83% after 10.3 years to 91% after 11.0 years (relative to the total number of deaths in the therapy arms of the respective safety populations) [27].

Standards for Adjuvant Systemic Therapy

Endocrine therapy, polychemotherapy and anti-HER2 therapy are undisputed standard therapies for adjuvant systemic therapy. Whether treatment is administered alone, sequentially or in combination depends on the subtype and on the risk factors [14–19].

Adjuvant endocrine therapy

Adjuvant endocrine therapy is indicated for patients with hormone receptor-positive breast cancer [17–19]. This therapeutic principle was first introduced for tamoxifen. In the meta-analysis by the Early Breast Cancer Trialists’ Group (EBCTCG) published in 1998, the effect of trastuzumab was investigated using the individual patient data of 37,000 women from 55 studies. After excluding data from 8000 so-called ER-poor patients with no or low ER expression (<10 fmol/mg cytosolic protein), a 5-year therapy regimen with tamoxifen showed a proportional reduction in the risk of recurrence by 47% and a reduction in mortality risk of 26% [28]. A subsequent meta-analysis by the EBCTCG using individual data from 10,386 women with ER-positive disease reported absolute improvements after 5, 10 and 15 years with 5 years of adjuvant tamoxifen therapy. For the whole population the recurrence rates were 11.4, 13.6 and 11.8%, and the mortality rates were 3.5, 7.6 and 7.9%, respectively (Table 1) [29]. With the same relative reduction of risk of 39%, tamoxifen therapy in lymph node-positive patients resulted in higher absolute improvements than for lymph node-negative patients: 16.1% after 5 years compared to 9.1% [29].

Treatment with aromatase inhibitors, which is recommended for the endocrine therapy of postmenopausal women, is another development in adjuvant endocrine therapy. Therapy options include the administration of aromatase inhibitors over a period of 5 years and therapy with different sequences of tamoxifen and aromatase inhibitors [2–3 years of tamoxifen followed by aromatase inhibitors for a total period of 5 years; 2–3 years of aromatase inhibitors followed by tamoxifen for a total period of 5 years;
5 years of tamoxifen followed by 5 years of aromatase inhibitors) [17, 18]. The standard duration of therapy is 5 years. An extended therapy regimen with aromatase inhibitors after 5 years of endocrine therapy may be administered after an individual analysis of the risks and benefits [18].

The additional effect of aromatase inhibitors compared to tamoxifen was investigated in a meta-analysis by the EBCTCG published in 2015 and based on the data of 31,920 women from 9 studies. Compared to 5 years of adjuvant therapy with tamoxifen, the 5-year therapy with aromatase inhibitors showed a relative reduction of the risk of recurrence by 20% and of the mortality risk by 11%. The absolute improvement in the rate of recurrence was 3.1% after 5 years and 3.6% after 10 years, and the absolute improvement in mortality rate was 1.2% and 2.7%, respectively (Table 1) [30]. The sequence tamoxifen for 2–3 years followed by aromatase inhibitor therapy up until the end of year 5 showed a relative reduction in the risk of recurrence and in the mortality risk of 18%, respectively, compared to 5 years of adjuvant tamoxifen therapy. The absolute improvement in recurrence rates was 2.6% after 5 years and 2.0% after 10 years, and the absolute improvement in mortality rates was 1.7 and 2.9%, respectively (Table 1) [30].

If the relative reduction of risk was the same for various subgroups, absolute improvements depended on the existing constellation of risk factors. The 5-year recurrence rate decreased, in absolute terms, by 1.2% for patients with node-negative disease, by 3.7% for patients with 1–3 positive lymph nodes and by 6.4% for women with more than 4 affected lymph nodes [30].

Another meta-analysis investigated the effect of aromatase inhibitors on postmenopausal women using published study data. Meta-analysis found significant benefits for DFS (HR = 0.70; 95% CI: 0.63–0.77) and OS (HR = 0.81; 95% CI: 0.71–0.93) after 5 years of adjuvant sequential therapy with tamoxifen followed by an aromatase inhibitor compared to 5 years of adjuvant therapy with tamoxifen. The same analysis reported a significant benefit for DFS (HR = 0.62; 95% CI: 0.52–0.74) but no benefit for OS (HR = 0.87; 95% CI: 0.66–1.16) for extended therapy with aromatase inhibitors after 5 years of therapy with tamoxifen [31].

### Adjuvant chemotherapy

Chemotherapy is an option to treat early-stage breast cancer with the exception of low-risk patients with HER2-negative hormone receptor-positive disease [14, 15, 18]. According to the German S3-guideline, adjuvant chemotherapy is indicated for HER2-positive tumors, non-endocrine sensitive tumors or when the tumor’s endocrine sensitivity is unclear, lymph node-positive disease, grade 3 tumors and for patients aged <35 years [17].

Several meta-analyses have shown that polychemotherapy significantly improves both the rate of recurrence and overall survival. The meta-analyses found a significant relative reduction of risk, irrespective of patient age, lymph node status, tumor size, tumor differentiation, estrogen receptor status or adjuvant treatment with tamoxifen [18, 19, 22]. Absolute benefits differed for patients with high absolute risk compared with patients with low absolute risk [28, 29, 32].

The introduction of a combination of cyclophosphamide, methotrexate and 5-fluorouracil (CMF) marked the start of adjuvant polychemotherapy [33]. The effect of this combination was analyzed in detail in the EBCTCG meta-analysis published in 2012, which was based on the individual data of 100,000 patients. The recurrence risk for patients who received standard doses of CMF chemotherapy decreased proportionally by 30% compared to patients who did not receive adjuvant chemotherapy. The absolute improvement in recurrence rates was 9.9% after 5 years and 11.2% after 10 years. The mortality risk decreased proportionally by 16%, with absolute improvements of 2.7 and 4.7% respectively after 5 and 10 years (Table 2) [32].

### Table 1 Relative and absolute reduction in the risk of recurrence and mortality for early breast cancer following adjuvant endocrine therapy [28, 29].

<table>
<thead>
<tr>
<th>Intervention</th>
<th>Patients (n)</th>
<th>Recurrence After 5 years</th>
<th>Mortality After 5 years</th>
<th>Recurrence After 10 years</th>
<th>Mortality After 10 years</th>
<th>Relative risk (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Rate Absolute difference</td>
<td>Rate Absolute difference</td>
<td>Rate Absolute difference</td>
<td>Rate Absolute difference</td>
<td></td>
</tr>
<tr>
<td>Tamoxifen (Tam) vs. no endocrine therapy (ET) [28]</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No ET</td>
<td>10 386</td>
<td>26.5%</td>
<td>−1.1%</td>
<td>38.3%</td>
<td>−13.6%</td>
<td>13.9%</td>
</tr>
<tr>
<td>5 years of Tam</td>
<td></td>
<td>15.1%</td>
<td></td>
<td>24.7%</td>
<td></td>
<td>10.4%</td>
</tr>
<tr>
<td>Aromatase inhibitor (AI) vs. tamoxifen [29]</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>5 years of Tam</td>
<td>9 885</td>
<td>12.1%</td>
<td>−3.1%</td>
<td>22.7%</td>
<td>−3.6%</td>
<td>0.80 (0.73–0.88)</td>
</tr>
<tr>
<td>5 years of AI</td>
<td></td>
<td>9.0%</td>
<td></td>
<td>19.1%</td>
<td></td>
<td>8.2%</td>
</tr>
<tr>
<td>5 years of Tam</td>
<td>11 798</td>
<td>12.1%</td>
<td>−2.6%</td>
<td>19.0%</td>
<td>−2.0%</td>
<td>0.82 (0.75–0.91)</td>
</tr>
<tr>
<td>2–3 years of Tam → AI up to year 5</td>
<td></td>
<td>9.5%</td>
<td></td>
<td>17.0%</td>
<td></td>
<td>7.1%</td>
</tr>
</tbody>
</table>
Table 2 Relative and absolute reduction in recurrence risk and mortality risk of patients with early breast cancer who received adjuvant polychemotherapy [30].

<table>
<thead>
<tr>
<th>Intervention</th>
<th>Patients (n)</th>
<th>Recurrence</th>
<th>Mortality</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Relative risk (95% CI)</td>
<td>After 5 years</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Rate</td>
<td>Absolute difference</td>
</tr>
<tr>
<td>Chemotherapy vs. no chemotherapy</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No chemo</td>
<td>5 253 (N + 34%)</td>
<td>30.2%</td>
<td>-9.9%</td>
</tr>
<tr>
<td>Standard CMF</td>
<td>20.3%</td>
<td>29.6%</td>
<td></td>
</tr>
<tr>
<td>Anthracycline (A) vs. CMF</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Standard CMF</td>
<td>5 122 (N + 61%)</td>
<td>32.9%</td>
<td>-0.5%</td>
</tr>
<tr>
<td>Standard 4AC</td>
<td>32.4%</td>
<td>41.0%</td>
<td></td>
</tr>
<tr>
<td>CMF</td>
<td>5 277 (N + 53%)</td>
<td>25.5%</td>
<td>-3.2%</td>
</tr>
<tr>
<td>A higher cumulative dose</td>
<td>22.3%</td>
<td>31.2%</td>
<td></td>
</tr>
<tr>
<td>Taxane (T) + anthracycline vs. anthracycline</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>A (more A)</td>
<td>33 084 (N + 82%)</td>
<td>22.0%</td>
<td>-2.8%</td>
</tr>
<tr>
<td>TA</td>
<td>19.2%</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>A (same A)</td>
<td>11 167 (N + 100%)</td>
<td>27.3%</td>
<td>-3.6%</td>
</tr>
<tr>
<td>TA</td>
<td>23.7%</td>
<td>30.2%</td>
<td></td>
</tr>
</tbody>
</table>

C: cyclophosphamide, M: methotrexate, F: 5-fluorouracil, N+: lymph node-positive patients

Adjuvant polychemotherapy first improved with the introduction of anthracyclines. This development was also analyzed in the EBCTCG meta-analysis of 2012. An anthracycline-based regimen consisting of doxorubicin and cyclophosphamide (AC) was not found to be more effective than standard CMF (cyclophosphamide, methotrexate, 5-fluorouracil) [30]. When higher-cumulative-dose anthracycline-based regimens were compared with CMF, the meta-analysis showed a relative reduction of 11% for the risk of recurrence. The absolute improvement in recurrence rates was 3.2% after 5 years and 2.6% after 10 years compared to CMF. This translated as a relative reduction in mortality risk of 16% and an absolute improvement in the mortality rate of 2.9% after 5 years and 3.9% after 10 years [32].

The addition of taxanes represent another step forward for adjuvant chemotherapy. Anthracycline- and taxane-based chemotherapy regimens are now a standard component of adjuvant systemic therapy [14–19].

Several meta-analyses have investigated the value of taxanes using published and aggregated outcomes, and came to similar results regarding the relative reduction of recurrence risk and mortality risk [34–38]. Examples include the results of the Cochrane meta-analysis which looked at 12 studies with a total of 21 191 patients. The Cochrane analysis found a significant improvement in DFS (HR = 0.81; 95% CI: 0.77–0.86) and OS (HR = 0.81; 95% CI: 0.75–0.88) for taxane-based adjuvant regimens compared to non-taxane-based adjuvant regimens. The analysis did not identify any subgroups which benefitted more or less from the adjuvant administration of taxanes [35].

The 2012 EBCTCG meta-analysis investigated the effect of taxanes based on individual patient data. According to this analysis, the additional administration of a taxane after combination therapy with anthracycline led to a relative reduction in the recurrence risk of 16% and a relative reduction in the mortality rate of 14% compared to the same anthracycline therapy without additional taxane administration. The absolute improvement in recurrence rates was 3.6% after 5 years and 4.6% after 8 years; the absolute improvement in mortality rate was 1.9% after 5 years and 3.2% after 8 years. When taxane-anthracycline combinations were compared with anthracycline regimens where the number of cycles in the control arm was increased as a counterbalance, the relative reduction in the recurrence risk was 14% and the relative reduction in the mortality risk was 10%. The absolute improvement in recurrence rate was 2.8% after 5 years and the improvement in mortality rate was 1.2% [32]. Compared to the results in this meta-analysis for patients who did not receive adjuvant chemotherapy, modern anthracycline- and taxane-based chemotherapy regimens achieved an absolute improvement in the recurrence rates of 10.9% after 5 years and 17.2% after 10 years and an absolute improvement in the mortality rates of 6.8 and 16.1%, respectively [32].

Table 2 Relative and absolute reduction in recurrence risk and mortality risk of patients with early breast cancer who received adjuvant polychemotherapy [30].

<table>
<thead>
<tr>
<th>Intervention</th>
<th>Patients (n)</th>
<th>Recurrence</th>
<th>Mortality</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Relative risk (95% CI)</td>
<td>After 5 years</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Rate</td>
<td>Absolute difference</td>
</tr>
<tr>
<td>Chemotherapy vs. no chemotherapy</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No chemo</td>
<td>5 253 (N + 34%)</td>
<td>30.2%</td>
<td>-9.9%</td>
</tr>
<tr>
<td>Standard CMF</td>
<td>20.3%</td>
<td>29.6%</td>
<td></td>
</tr>
<tr>
<td>Anthracycline (A) vs. CMF</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Standard CMF</td>
<td>5 122 (N + 61%)</td>
<td>32.9%</td>
<td>-0.5%</td>
</tr>
<tr>
<td>Standard 4AC</td>
<td>32.4%</td>
<td>41.0%</td>
<td></td>
</tr>
<tr>
<td>CMF</td>
<td>5 277 (N + 53%)</td>
<td>25.5%</td>
<td>-3.2%</td>
</tr>
<tr>
<td>A higher cumulative dose</td>
<td>22.3%</td>
<td>31.2%</td>
<td></td>
</tr>
<tr>
<td>Taxane (T) + anthracycline vs. anthracycline</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>A (more A)</td>
<td>33 084 (N + 82%)</td>
<td>22.0%</td>
<td>-2.8%</td>
</tr>
<tr>
<td>TA</td>
<td>19.2%</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>A (same A)</td>
<td>11 167 (N + 100%)</td>
<td>27.3%</td>
<td>-3.6%</td>
</tr>
<tr>
<td>TA</td>
<td>23.7%</td>
<td>30.2%</td>
<td></td>
</tr>
</tbody>
</table>
Adjuvant anti-HER2 therapy

According to the current clinical therapy guidelines, adjuvant therapy with trastuzumab for 1 year is indicated for patients with HER2-positive early breast cancer. For patients with node-negative disease, the indication is defined according to tumor size: some guidelines recommend adjuvant therapy with trastuzumab for tumor diameters > 5 mm [15, 16, 18], and all guidelines recommend adjuvant therapy with trastuzumab for tumors with diameters of 1 cm and above [15 – 18].

Adjuvant targeted anti-HER2 therapy was introduced with trastuzumab. There are a number of meta-analyses on the effect of anti-HER2 therapy, but none of them are yet based on individual patient data. The meta-analyses all found significant increases in DFS and OS after adjuvant anti-HER2 therapy with trastuzumab [39–41]. The Cochrane meta-analysis was the most comprehensive analysis, comprising 8 studies on early HER2-positive breast cancer. According to the Cochrane analysis, the relative reduction in recurrence risk was 40% (HR for DFS = 0.60; 95% CI: 0.50–0.71) and the relative reduction in mortality risk was 34% (HR for OS = 0.66; 95% CI: 0.57–0.77) for trastuzumab-containing regimens compared to regimens without trastuzumab [23]. The meta-analysis provided no data on absolute improvement rates. In drug approval studies, the improvement in DFS was reported to be 5.9–9% after 5 years and 5.1–11.5% after 10 years, and the improvement in OS was 2.4–5% after 5 years and 4.6–8.8% after 10 years [24 – 26, 42, 43].

Escalation and de-escalation of adjuvant systemic therapy

Dose-dense chemotherapy, which represents an escalation of adjuvant systemic therapy, clearly shows that the magnitude of the additional benefit achieved with a new adjuvant therapy depends on the patient’s baseline risk. Dose-dense chemotherapy is the therapy of choice for a high-risk subpopulation of patients with early breast cancer and large tumor burden [18]. Currently there are only meta-analyses based on published data [44–46] which consistently show a benefit for dose-dense chemotherapy compared to conventional chemotherapy. The most extensive analysis with a total of 17,188 patients from 8 studies reported a relative reduction of recurrence risk by 16% (HR (DFS) = 0.84; 95% CI: 0.77–0.91) and a reduction of the mortality risk by 14% (HR (OS) = 0.86; 95% CI: 0.79–0.93) [46]. The risk profiles of the investigated study populations differed. Individual studies which included patients with a particularly high baseline risk showed a greater benefit for patients [47]. The German ETC study only included patients with more than 4 positive lymph nodes [48, 49]. The risk of recurrence after 5 and 10 years for these women treated with dose-dense chemotherapy decreased proportionally compared to conventional chemotherapy by 28% and 26%, respectively. This corresponds to a benefit in absolute terms of 8% and 9%, respectively. Patients’ mortality risk after 5 and 10 years had decreased proportionally by 24% and 28%, respectively; this corresponds to an absolute improvement of 5% and 10%, respectively [48, 49].

It is important to mention that de-escalation of systemic therapy is discussed and even recommended for specific subgroups of patients with early breast cancer and a very low risk of recurrence [14, 18]. In a large phase II study, in which patients with HER2-positive early breast cancer, negative lymph node status and tumor diameters < 3 cm received deescalated chemotherapy (i.e. only paclitaxel in combination with trastuzumab without additional anthracyclines), the 7-year rate for DFS was 93.3% (95% CI: 90.4–96.2%), the breast-cancer specific survival rate was 98.6% (95% CI: 97.0–100%). Only 1% of patients developed distant recurrence [50].

Multigene signatures

A number of multigene signatures have been developed which aim to identify those patients with early breast cancer whose prognosis is so favorable that it is worth discussing whether chemotherapy might be dispensed with [51]. According to the recommendations of the AGO, methodologically standardized and clinically validated multigene tests could be useful for women with hormone receptor-positive, HER2-negative, node-negative early breast cancer as the findings could be used to support decisions for or against adjuvant chemotherapy when conventional prognostic parameters including Ki-67 do not support a definitive decision [18]. This recommendation was based on data from large prospective/retrospective studies and the initial results of prospective studies [52–67]. In one study, the 3-year DFS of patients with early, hormone receptor-positive, HER2-negative breast cancer and a low recurrence score (RS) ≤ 11 who received endocrine therapy alone was 98% even without adjuvant chemotherapy [65]. Another study reported a DFS of 93.8% and an OS of 98% after 5 years for patients with hormone receptor-positive, HER2-negative, lymph node-negative tumors and a low RS (< 11) following endocrine therapy alone [66].

Tools to Assess Clinical Benefit in Oncology

Defining the term clinical benefit in the context of therapies for early breast cancer is currently a challenge.

There are a number of different national institutions which systematically assess health-relevant technologies. They include the National Institute for Health and Care Excellence (NICE) in the United Kingdom, the Haute Autorité de Santé (HAS) in France and the Gemeinsamer Bundesausschuss (G-BA, Federal Joint Committee) supported by the Institut für Qualität und Wirtschaftlichkeit (IQWiG, Institute for Quality and Efficiency in Healthcare) in Germany. NICE appraises therapies to obtain standardized health economic assessment measures such as QALY (quality-adjusted life years) and ICER (incremental cost-effectiveness ratio), which are independent of specific indications [68]. After considering the severity of disease, efficacy, adverse events, therapeutic value compared with other available therapies, and public health benefits, HAS assesses the actual clinical benefit of therapies by first categorizing them as insufficient or sufficient, then rating the benefit as “low”, “moderate” or “substantial”. HAS also assesses therapies for their clinical added value based on their comparative efficacy and safety, rating the clinical added value as either “major”, “substantial”, “moderate”, “minor” or “no improvement”. The parameters determining classification into the individual categories are not described [69]. The IQWiG provides concrete thresholds in the form of the upper limit of the 95% confi-
dence interval for the relative risk, using figures obtained to assess the extent of the additional benefit for the categories “mortality”, “morbidity”, “health-related quality of life” and “adverse events”. The additional benefit achieved in each of these categories may be rated as major (overall mortality < 0.85; severe symptoms, adverse events and quality of life > 0.95), considerable (overall mortality > 0.90; non-severe symptoms and adverse events < 0.90), minor (overall mortality > 1.00; severe symptoms, adverse events and quality of life < 1.00; non-severe symptoms and adverse events < 0.90), or no or only minimal additional benefit. The overall additional benefit provided by an intervention is based on the assessments for the above listed categories [70]. Neither the IQWiG nor the G-BA have published a definitive algorithm determining the additional benefit.

The assessment methods used by this and other HTA institutions do not differentiate between different medical specialties. They use no special methods or parameters to assess systemic oncologic therapies [48–50].

However, two well-known medical societies recently developed tools which aim to provide a standardized and systematic evaluation of the clinical benefit of new systemic oncologic therapies. These tools are the Value Framework of the ASCO and the Medical Oncology Magnitude Clinical Benefit Scale (MCBS) of the ESMO [1,2].

To assess adjuvant therapies, the ASCO uses the hazard ratio for OS and compares the new therapy with a control therapy. If the HR for OS is not reported, the ASCO uses the HR for DFS. The hazard ratio is classified into 1 of 5 categories depending on the magnitude of the HR. The maximum score is 80 points. A therapy with a HR for DFS > 0.85 will receive 0 points, a therapy with a HR for DFS of between 0.84 and 0.71 is given 15 points, and a therapy with a HR < 0.20 will achieve 80 points. In a second step, the difference between the two therapies with regard to grade 3–5 toxicity is also assigned to one of 5 categories. The score for toxicity difference ranges from +20 for significantly lower toxicity to –20 for significantly higher toxicity. The final score calculated from the two scales is known as the net health benefit (NHB); the maximum possible number of points is 100. The final score for the therapy is reported descriptively as x number of points out of a maximum possible number of 100 points together with the costs of the new medication in the USA. No threshold values for a clinically relevant benefit are defined and no evaluations are made [1].

The ESMO developed and validated the MCBS as a tool to determine the clinical benefit of new systemic therapies. In contrast to the tool described above, the MCBS evaluates clinical benefit in terms of clinical relevance. Three categories – A, B and C – are used to evaluate adjuvant therapies. Category C indicates that there is no clinically relevant benefit. The classification is based on the benefits of the new therapy with regard to the endpoints OS or DFS, if OS is not available. Toxicity, quality of life and costs of therapy are included in the assessment if the new therapy is shown to be not inferior with regard to OS and DFS (Fig. 1). The highest clinically relevant benefit (grade A) is achieved if the absolute improvement in mortality after at least 3 years is more than 5%. If the OS data is immature, there must be a significant improvement in DFS with a lower limit of the 95% confidence interval (CI) of less than 0.65 to achieve grade A. A clinically relevant benefit for the second highest category B is present if there is an absolute improvement in mortality after at least 3 years of 3–5%. If the OS is immature, a significant improvement in DFS where the lower limit of the 95% CI is 0.65–0.8 is required to achieve 40 points.

### Table: ESMO Medical Oncology Magnitude of Clinical Benefit Scale (MCBS)

<table>
<thead>
<tr>
<th>Grade A, if one of the following criteria apply</th>
<th>Grade B, if one of the following criteria apply</th>
<th>Grade C, if one of the following criteria apply</th>
</tr>
</thead>
<tbody>
<tr>
<td>Improvement of OS: &gt;5% after ≥ 3 years of follow-up</td>
<td>Improvement of OS: 3–5% after ≥ 3 years of follow-up</td>
<td>Improvement of OS: &lt; 3–5% after ≥ 3 years of follow-up</td>
</tr>
<tr>
<td>Improvement of DFS (if primary endpoint) in study with no mature survival data: lower limit of the 95% CI &lt; 0.65</td>
<td>Improvement of DFS (if primary endpoint) in study with no mature survival data: lower limit of the 95% CI 0.65–0.8</td>
<td>Improvement of DFS (if primary endpoint) in study with no mature survival data: lower limit of the 95% CI &gt; 0.8</td>
</tr>
<tr>
<td>Non-inferiority of OS or DFS and lower toxicity of therapy or improved quality of life (measured using validated tools)</td>
<td>Non-inferiority of OS or DFS and lower cost of treatment</td>
<td></td>
</tr>
</tbody>
</table>

ESMO: European Society of Medical Oncology
OS: Overall survival
DFS: Disease-free survival
KI: Confidence interval

**Fig. 1** ESMO Medical Oncology Magnitude of Clinical Benefit Scale (MCBS): assessment criteria for new adjuvant, neoadjuvant and potentially curative therapies [2].
grade B. If OS and DFS of the new therapy are not inferior to those of controls in non-inferiority studies, then the new therapy must additionally show either reduced toxicity or better quality of life or the costs of treatment must be lower for the new therapy to be categorized as offering a clinically relevant benefit (grade B) [2].

Summary and Conclusions

The goal of adjuvant therapy is to improve curative options even further.

Given the above stated aim, assessment of the clinical benefit of an adjuvant therapy for early breast cancer is largely based on efficacy endpoints, although findings for toxicity and quality of life are also taken into account when deciding for or against a specific adjuvant therapy.

Because the mortality rate has decreased significantly in recent years, a benefit in terms of overall survival can only be determined after many years of follow-up. Disease-free survival, which has been accepted as a surrogate marker for overall survival [2, 71, 72], has therefore become more important for the assessment of treatment modalities [1, 2, 12, 13]. In a curative setting, a relapse with recurrence of disease is per se a relevant event for the patient.

The evidence from existing adjuvant therapy standards provides a good scale against which the clinical benefit of new adjuvant therapies for patients with early breast cancer can be measured. It is important to remember, however, that the benefit of established adjuvant therapies in terms of reduced risk of recurrence only began to emerge after 2 to 3 years of follow-up and continued to increase until 5 years of follow-up [28 – 30, 32]. The introduction of the therapeutic principles of adjuvant endocrine therapy, polychemotherapy and anti-HER2 therapy led to a reduction in the risk of recurrence by 30–50%. Absolute differences in recurrence risk after 5 years were 11.4% [23, 28 – 30, 32]. Current therapy standards such as chemotherapy with anthracyclines and taxanes or endocrine therapy with aromatase inhibitors over a period of 5 years are further developments of the principles of adjuvant therapy. They have led to more moderate reductions in the recurrence risk of 11–16% and 18–30%. The absolute improvement after 5 years was 3.6% [28 – 32]. The MCBS of the ESMO requires improvements of a similar magnitude. However, the MCBS does not use absolute improvements measured at specific time-points to assess DFS but uses the hazard ratio instead. According to the MCBS, a new adjuvant therapy offers a clinical benefit if the lower limit of the 95% CI for DFS is < 0.8 [2]. It should also be mentioned that improvements of this magnitude reported for taxanes and aromatase inhibitors provided the basis for the approval of these treatment modalities and led to their inclusion in guideline recommendations [73 – 75].

In consequence, new drugs to treat patients with early breast cancer should be considered as offering a clinical benefit if they lead a further reduction in the risk of recurrence and the magnitude of the reduction corresponds to that of current therapy standards. After a lengthy period of follow-up the reduction in recurrence risk should also translate into a survival benefit without the patient suffering a lasting adverse effect from toxicities.

Ultimately the question regarding the clinical relevance of a new therapy must be answered individually for each patient. There is a considerable difference in expectations. A German study which surveyed 2155 patients and 527 physicians highlighted the breadth of expectations and the extent of the discrepancy between the expectations of patients and those of their physicians with regard to the benefit of adjuvant therapies. One third of patients and a considerable percentage of physicians had unrealistic assumptions about the expected increases in 5-year survival rates following adjuvant chemotherapy, endocrine therapy or antibody therapy [76]. Because of this, when making an informed decision it is useful to consider the expected benefit in the context of the parameters used to assess established therapy standards.

Conflict of Interest

Volker Möbus was a consultant for Amgen, Celgene and Roche and has received consulting fees from Amgen and Celgene. Susanne Hell has received consulting fees from Genomic Health and is employed by Roche Pharma AG. Marcus Schmidt was a consultant for Astra Zeneca, Celgene, Eisai, Myriad, Novartis, Pfizer, Pierre-Fabre, Roche, Sividon and has also received consulting fees from these companies.

Update (13.11.2017)

In the meantime an updated version 1.1 of the ESMO MCBS was published. For new approaches to adjuvant or potentially curative therapies a clinical benefit of Grade C is also assigned based on improvements in pathologic complete response rate (pCR) alone, if primary endpoint, by ≥ 30% relative and ≥ 15% absolute gain in studies without mature survival data [Cherny NI, Dafni U, Bogaerts J et al. ESMO-Magnitude of Clinical Benefit Scale version 1.1. Ann Oncol 2017; 28: 2340–2366]. Otherwise all statements in this review paper regarding the ESMO MCBS still apply.

References


[49] Moebus V, Jackisch C, Lueck HJ et al. Intense dose-dense sequential chemotherapy with epirubicin, paclitaxel, and cyclophosphamide compared with conventionally scheduled chemotherapy in high-risk primary breast cancer patients with ≥ 4 positive lymph nodes. SABCS 2012; Abstr. S3-04

[50] Tolany SM, Barry WT, Guo H et al. Seven-year (yr) follow-up of adjuvant paclitaxel (T) and trastuzumab (H) (APT) trial for node-negative, HER2-positive breast cancer (BC). J Clin Oncol 2017; 35 (no. 15_suppl): 511


[72] Gill S, Sargent D. End points for adjuvant therapy trials: has the time come to accept disease-free survival as a surrogate end point for overall survival? Oncologist 2006; 11: 624–629


